Your body's own balancing network — and why one compound in copaiba reaches it directly.
~14 min read
You learned about the nervous system and the immune system at school. You almost certainly did not learn about this one, because it was only identified in the early 1990s — which makes it, by the standards of anatomy, a very recent discovery.
The endocannabinoid system, usually shortened to ECS, is not an organ or a place in the body. It is a signalling network that runs through the central and peripheral nervous system and through immune tissue, and its job is regulation: keeping other systems inside their working range. Mood, appetite, the inflammatory response, how readily you relax — all of these have an ECS component.
The clearest way to think about it is as a thermostat rather than a heater. It does not drive a process; it senses when a process has drifted and nudges it back. That is why it comes up in so many different contexts, and why it is worth a healer understanding: it is a system whose whole purpose is balance.
Receptors
Docking points on the surface of cells. The signal only lands where there is a receptor to receive it, which is why location decides effect.
Cannabinoids
The messenger molecules themselves. Your body makes its own; plants make their own; laboratories make a third kind.
Enzymes
The clean-up crew. They break messengers down once the message has been delivered, so a signal is a pulse rather than a permanent state.
Diagram to come
Simple line-art body showing the ECS as a network rather than an organ: receptor clusters marked in the brain and spinal cord (CB1) and through immune tissue and the periphery (CB2), with the three components labelled — receptors, cannabinoids, enzymes.
There are two main receptors in this system, and almost everything that is confusing about cannabinoids becomes clear once you can tell them apart. They are called CB1 and CB2, and they sit in different parts of the body.
| CB1 | CB2 | |
|---|---|---|
| Mostly found in | Brain and spinal cord | Immune system and peripheral tissue |
| Associated with | Mood, memory, perception of discomfort | Immune signalling and the body’s natural response to irritation |
| Activation can be | Psychoactive — this is the receptor responsible for those effects | Not psychoactive |
The single most useful fact in this lesson
CB1 is the receptor behind psychoactive effects. CB2 is not. A compound that binds CB2 and leaves CB1 alone can work within this system without any of the effects people associate with cannabis. That distinction is the whole reason copaiba is interesting.
A receptor is not a switch that produces one fixed outcome. It is a shape on a cell surface, and what happens when something binds to it depends entirely on what that cell does for a living. The same signal arriving at a neuron and at an immune cell produces two different downstream events, because the two cells have different machinery behind the door.
This is why "activates the endocannabinoid system" is a nearly meaningless phrase on its own, and why you should be sceptical when you read it. The useful question is always: which receptor, in which tissue, and how strongly.
The word "cannabinoid" describes a role, not an origin. It means a molecule that interacts with this system. They reach it from three directions.
Endocannabinoids — made by you
Your body synthesises its own, on demand, and breaks them down shortly after. This is the system working normally, every day, without any input from outside.
Phytocannabinoids — made by plants
Plants produce compounds that happen to fit the same receptors. Cannabis is the famous example, but it is far from the only one: black truffle, cacao, and several essential oils contain them too.
Synthetic — made in a laboratory
Manufactured to bind these receptors, usually far more strongly than anything found in nature. Not relevant to anything in this app, but worth knowing the category exists.
The middle category is the one that matters here. A phytocannabinoid is not a drug that has been added to a plant — it is part of the plant’s own chemistry, produced for the plant’s own reasons, which happens to be recognised by a receptor in your body. Among essential oils, the ones that carry them include copaiba, black pepper and melissa.
Photograph to come
Copaiba resin being tapped from the trunk of a copaifera tree in Brazil — the raw material, before distillation. Warm, real, hands-in-the-work rather than a product shot.
Two compounds can both be described as "working with the endocannabinoid system" and behave completely differently. The difference is usually how directly they bind.
A molecule that fits a receptor closely and holds on produces a response quickly and strongly. A molecule that does not fit well, or that influences the system some other way without ever docking, produces a slower and more diffuse response. Both are real. They are not the same thing, and the literature suggests these compounds tend to be selective about which receptor they act on.
This is the principle to carry out of this lesson and reuse everywhere else: with any plant compound, ask how directly it acts. It explains far more than potency or dose does.
Chemists describe how tightly a molecule binds a receptor as its affinity. High affinity means the molecule finds the receptor readily and stays docked long enough to produce a clear signal. Low affinity means it binds loosely, briefly, or only at concentrations you would never reach in practice.
There is also a difference between binding a receptor and changing how a receptor behaves. Some compounds never dock at all, but alter the surrounding environment so that the body’s own messengers last longer or land more effectively. That is a genuine mechanism — it is simply an indirect one, and indirect mechanisms tend to be slower and harder to predict.
Beta-caryophyllene — usually written BCP — is a sesquiterpene, one of the larger building-block structures you met in the terpenes lesson. It is unusual among essential oil constituents because it binds directly to CB2 receptors. Not indirectly, not by influencing the environment: it docks.
That makes it a dietary cannabinoid, which is a genuinely surprising fact about an ordinary plant compound. And because it acts at CB2 and not CB1, it does so without psychoactive effects.
| Oil | Typical BCP content | Also known for |
|---|---|---|
| Copaiba | 45–65% | The highest BCP content in the doTERRA range |
| Black Pepper | Substantial | Warming aroma; used in cooking and topically |
| Melissa | Present | Calming aromatic profile |
| Deep Blue (via copaiba) | Contributed by the copaiba in the blend | Muscles and joints after effort |
| Adaptiv (via copaiba) | Contributed by the copaiba in the blend | Nervous system balance under stress |
Notice the last two rows. Copaiba does not only appear as a single oil — it is inside blends you may already use daily. Part of what those blends are doing is delivering BCP.
Diagram to come
Skeletal structure of beta-caryophyllene, labelled, with the sesquiterpene backbone (15 carbons) highlighted so it connects back to the terpenes lesson.
It did not. The copaifera tree makes BCP for its own reasons — resin chemistry that defends the tree and seals damage, the same four jobs plant compounds do everywhere. Nothing about it was shaped for us.
What is actually going on is convergence. Receptors recognise shapes, and there are only so many shapes. A molecule shaped by nature for a completely unrelated purpose in a tree can happen to have a region that fits a receptor in an animal. This happens more often than it sounds like it should, and it is the underlying reason plant chemistry interacts with human physiology at all.
It is also a useful corrective to two opposite errors: that plant compounds are meaningless because they were not designed for us, and that they were somehow put here for our use. Neither is right. The interaction is real, and it is a coincidence of shape.
The ECS is where BCP is most discussed, but doTERRA’s education team has highlighted several other targets it appears to interact with. These are worth knowing because they explain why copaiba shows up in contexts that have nothing obvious to do with cannabinoids.
CD14 receptor
Associated with pathways involved in a healthy inflammatory response.*
μ-opioid receptor
Associated with pathways involved in overall body comfort.*
α7-nACHR receptor
Associated with pathways involved in cognitive function.*
* These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. All compound-level statements refer to the chemical constituent, not to a finished product.
This is the question people actually ask out loud, usually phrased as "isn’t copaiba just CBD?" It is not, and the reasons are specific rather than promotional.
Both interact with the endocannabinoid system, which is why the comparison gets made at all. But they reach it differently, and they are different kinds of substance.
| Copaiba (beta-caryophyllene) | CBD | |
|---|---|---|
| What it is | An essential oil, steam distilled from tree resin | An isolate — a single compound extracted from the cannabis plant |
| How it reaches the ECS | Binds directly to CB2 | Does not bind either receptor effectively; acts indirectly |
| Speed of response | Direct binding produces a faster response | Indirect action produces a slower one |
| Psychoactive | No — acts at CB2, not CB1 | No |
| Usually sold as | The whole oil | An isolate, typically diluted in a carrier oil |
doTERRA’s Director of Education, Scott Johnson, has described CBD as a helper molecule — something that signals the ECS to work more efficiently and modulates how the body responds to the compounds that do bind directly. That is a fair description of an indirect mechanism, and it is not a dismissal. It is simply a different mode of action.
Why doTERRA does not carry CBD
CBD is an isolate rather than an essential oil, so it falls outside what CPTG testing is built to verify — and an isolate usually arrives already diluted in a carrier, which is not a form the purity standard can speak to. That is the stated reason it is not in the product line.
One frequently quoted figure deserves a date attached to it: a 2017 review of CBD products on sale found a large proportion were mislabelled, with contents differing from what the label claimed. That was 2017. The market and its regulation have both moved considerably since, so treat that number as a historical finding rather than a description of today.
The legal status of CBD also differs substantially from country to country, including across the markets this app serves. Nothing here is guidance about obtaining or using it — the point of this section is to explain the mechanism clearly enough that you can answer the question when someone asks you.
Copaiba is gentle, which makes it one of the more forgiving oils to work with. It has very little aroma compared with most — a soft, woody, almost sweet note that disappears into a blend rather than dominating it.
Aromatic
Diffuse for a calm, grounded environment. It layers well underneath brighter oils rather than competing with them.
Topical
Apply 1–2 drops diluted in a carrier oil to the area you want to support, or to the bottoms of the feet. Dilution improves absorption and reduces the chance of sensitivity.
Internal
Copaiba is labelled for internal use. One drop in a veggie capsule or a glass of water — glass or stainless steel, never plastic. Supports a healthy inflammatory response when taken internally.*
* These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Only consume oils whose label states they are for internal use.
Video to come
Link a doTERRA video on Copaiba — the oil overview or the sourcing story from Brazil. Either works; the sourcing one pairs better with the Sourcing lesson in the Foundation course.
Understanding a mechanism is only worth the time if it changes what you actually do. Four things follow from this lesson.
Where this connects
Beta-caryophyllene reappears in the Nervous System lesson, where it is one of the calming constituents in Adaptiv, and in the Musculoskeletal lesson, where copaiba contributes to Deep Blue. Same compound, same CB2 mechanism, two different tissues — which is section two of this lesson in action.
Lesson 11 of 18 · Science